Clinical Trials Browser

Phase 2 × Recruiting × Everolimus × Clear all

NCT05773274 2026-03-18

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Phase 2 Recruiting

Metastatic Digestive System Neuroendocrine Tumor G1

NCT04665739 2026-03-17

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Phase 2 Recruiting

Advanced Lung Neuroendocrine Tumor

NCT05843253 2026-03-04

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Phase 2 Recruiting

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma

NCT06955169 2026-02-17

MOMENTUM-1

Phase 2 Recruiting

Meningioma

NCT05933395 2026-01-20

GERTRUDE

Phase 2 Recruiting

Neoplasm Metastasis

NCT06428396 2025-12-26

LITESPARK-029

Phase 2 Recruiting

Breast Neoplasms

NCT06326190 2025-09-16

LUMEN-1

Phase 2 Recruiting

Meningioma

NCT02029001 2025-08-07

MOST plus

Phase 2 Recruiting

Neoplasm Metastasis

NCT06126588 2025-03-11

ELUMEN

Phase 2 Recruiting

Meningioma

NCT06482086 2024-12-05

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Phase 2 Recruiting

Locally Advanced Thyroid Gland Carcinoma

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT04803318 2024-06-25

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT06472388 2024-06-25

EVENET

Phase 2 Recruiting

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors, Disease Progression

NCT05949541 2024-02-08

BCTOP-L-M01

Phase 2 Recruiting

Breast Neoplasms

NCT06211790 2024-01-18

Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma

Phase 2 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05983107 2023-08-09

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Phase 2 Recruiting

HR+/HER2- Advanced Breast Cancer

NCT05725200 2023-02-21

EVIDENT

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms